AimTo investigate the post‐treatment effect of dorzagliatin in drug‐naïve patients with type 2 diabetes (T2D) regarding the achievement of stable glycaemic control and drug‐free diabetes remission.Materials and MethodsPatients who completed dorzagliatin treatment in the SEED trial and achieved stable glycaemic control were enrolled in this 52‐week study without any antidiabetic medication. The primary endpoint was the diabetes remission probability at week 52 using the Kaplan–Meier method. The potential factors that contribute to stable glycaemic control and diabetes remission based on the characteristics of patients before and after treatment with dorzagliatin were analysed. A post hoc sensitivity analysis of diabetes remission probability using the American Diabetes Association (ADA) definition was conducted.ResultsThe Kaplan–Meier remission probability was 65.2% (95% CI: 52.0%, 75.6%) at week 52. Based on the ADA definition, the remission probability was 52.0% (95% CI: 31.2%, 69.2%) at week 12. The significant improvements in the insulin secretion index ΔC30/ΔG30 (41.46 ± 77.68, P = .0238), disposition index (1.22 ± 1.65, P = .0030), and steady‐state variables of HOMA2‐β (11.49 ± 14.58, P < .0001) and HOMA2‐IR (−0.16 ± 0.36, P = .0130) during the SEED trial were important factors in achieving drug‐free remission. A significant improvement in time in range (TIR), a measure of glucose homeostasis, in the SEED trial from 60% to more than 80% (estimated treatment difference, 23.8%; 95% CI: 7.3%, 40.2%; P = .0084) was observed.ConclusionsIn drug‐naïve patients with T2D, dorzagliatin treatment leads to stable glycaemic control and drug‐free diabetes remission. Improvements in β‐cell function and TIR in these patients are important contributors to diabetes remission.
Objective: We attempt to explore the pathogenesis and specific genes with aberrant expression in diabetic nephropathy (DN). Methods: The gene expression profile of GSE1009 was downloaded from Gene Expression Omnibus database, including 3 normal function glomeruli and DN glomeruli from cadaveric donor kidneys. The differentially expressed genes (DEGs) were analyzed and the aberrant gene-related functions were predicted by informatics methods. The protein-protein interaction (PPI) networks for DEGs were constructed and the functional subnetwork was screened. Results: A total of 416 DEGs were found to be differentially expressed in DN samples comparing with normal controls, including 404 up-regulated genes and 12 downregulated genes. DEGs were involved in the process of combination to saccharides and the decline of tissue repairing ability of the organisms. The genes of VEGFA, ACTG1, HSP90AA1 had high degree in the PPI network. The main biological process of genes in the sub-network was related with cell proliferation and signal transmitting of cell membrane receptor. Conclusion: Significant nodes in PPI network provide new insights to understand the mechanism of DN. VEGFA, ACTG1 and HSP90AA1 may be the potential targets in the DN treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.